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Primary human immunodeficiency type 1 viruses (HIV-1) resist antibody neutralization but become sensitive after passage through T cell lines.
We and others previously reported an increased neutralization sensitivity of HIV-1 after prolonged culture on primary peripheral blood
mononuclear cells (PBMC). Hence we hypothesized that adaptation to growth in T cell lines is in fact selection of a pre-existing neutralization-
sensitive HIV-1 variant from the quasispecies in the PBMC culture. Indeed, increased neutralization sensitivity was associated with largely
identical synonymous and non-synonymous mutations between progeny of parallel H9 passages from the same split inoculum from 2 of 3 viruses.
H9 T cell line adaptation of molecular cloned HIV-1 was less successful and associated with only a few de novo mutations that varied between
parallel H9-adapted progeny from the same split inoculum. We conclude that T cell line adaptation of HIV-1 can indeed select for a pre-existing
variant but that this most likely depends on the viral diversity in the inoculum.
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Primary human immunodeficiency virus type 1 (HIV-1)
usually resists neutralization by antibodies. This phenotype
interferes with the efficacy of neutralizing antibodies in vivo,
and has turned out to be a significant obstacle in vaccine design
strategies. The neutralization sensitivity of HIV-1 increases after
adaptation of the virus to replication in immortalized T cell lines
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doi:10.1016/j.virol.2006.09.021primary HIV-1, T cell line-adapted (TCLA) variants are
considered to have a more open envelope conformation which
would be more easily accessible to antibodies. Indeed,
antibodies generated against monomeric gp120 and immune
sera of HIV-1-infected patients, can neutralize TCLA but not
primary HIV-1 (Beddows et al., 1999; Binley et al., 2000;
Broder et al., 1994; Ortiz et al., 1999; Stamatatos et al., 1994;
Sullivan et al., 1995; Ugolini et al., 1997). Antibodies that lack
neutralizing activity against primary HIV-1 are mostly directed
to defective or monomeric gp120 molecules, whereas neutraliz-
ing antibodies have the unique ability to bind the properly
folded oligomeric envelope complex (Moore et al., 2006).
We and others have shown that neutralization-sensitive HIV-1
variants can also emerge during prolonged in vitro culture on
primary peripheral blood mononuclear cells (PBMC) (Beau-
mont et al., 2004; Pugach et al., 2004). Based on these
observations we hypothesized that adaptation to growth in T
cell lines is in fact the selection of a pre-existing neutralization-
Fig. 1. Schematic overview of serial H9 cell line passages of the biological and
molecular cloned HIV-1 isolates. As described in Materials and methods, from
each virus the 1st passages were performed by co-culture of H9 cells with split
inocula of infected PBMC, 2nd and 3rd passages were performed with a fixed
volume of cell-free supernatant from the preceding H9 passage.
Table 2
Culture time in days of split inoculum until first detection of gag p24 antigen
production
Virus Passage 1 Passage 2
BC-ACH039.24E6a a 32 10
b 35 10
c 35 10
d 35 10
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culture. To test this hypothesis, we set up an experimental design
that allowed us to use the ability of an HIV-1 isolate to replicate
in theH9 Tcell line as an indicator of the presence of pre-existing
neutralization-sensitive HIV-1 variants in the quasispecies of the
PBMC culture. Our data suggest that T cell line passage can
select for pre-existing variants in the inoculum but that
adaptation can also occur via novel mutations, probably
depending on the homogeneity of the viral inoculum. T cell
line-tropic HIV-1 variants may emerge frequently during
prolonged culture in PBMC which underscores the use of
molecular clones of HIV-1 as standards in neutralization assays
because of their stable phenotypes.
Results
T cell line adaptation of biological cloned HIV-1
To test the hypothesis that T cell line adaptation of HIV-1 is
selection of a pre-existing virus variant from a PBMC grown
viral quasispecies, PBMC infected with 1 of 3 biologically
cloned (BC) HIV-1 isolates (BC-ACH039.24E6a, BC-
ACH208.22F1a and BC-ACH208.13B1) were used for co-
cultivation with the H9 T cell line (Table 1). All viruses were
previously documented to use only CXCR4 (van Rij et al.,
2000). PBMC cultures productively infected with one of the
viruses were split in four equal aliquots (a–d) that were co-
cultured with H9 cells in four separate parallel cultures (p1;
Fig. 1). At day 28, p24 levels in all cultures had become
undetectable, indicating that the remaining PBMC in the co-
culture no longer produced viral progeny above the limit of
detection of our in-house ELISA. Evidence for p24 production
above this detection limit was first achieved between days 32
and 35 for the four parallel co-cultures infected with BC-
ACH039.24E6a, between days 32 and 42 for the four parallel
co-cultures infected with BC-ACH208.22F1a and between
days 57 and 70 for the four parallel co-cultures infected with
BC-ACH208.13B1 (Table 2). This variation in culture time
before first detection of virus production was also observed forTable 1
Characteristics of HIV-1 isolates used for H9 T cell line passage
Patient Virus isolate Moment
of virus
isolation a
No. of cell line
passages
Co-
receptor
usage
Parallel b Sequential c
ACH039 .24E6a 29 4 2 CXCR4
ACH208 .13B1 19 4 2 CXCR4
ACH208 .22F1a 46 4 2 CXCR4
ACH320 .3.1 3 4 1 CXCR4
ACH320 .2A 1.2 2.3 4 2 CXCR4
pLAI/H8/E370 NA 4 2 CXCR4
pLAI/Han2 NA 4 0 CXCR4
NA: not applicable (these are chimeric molecular HIV clones).
a In months after seroconversion.
b Split inocula of each virus were used to infect four parallel H9 T cell line
cultures.
c p24-positive parallel passages were again transferred to fresh HIV negative
H9 T cell line cultures (see Fig. 1).the second H9 cell line passages (p2) albeit that all viruses had
an earlier first day of detection (day 10, between days 10 and
46 or between days 24 and 61 for the parallel co-cultures of
BC-ACH039.24E6a, ACH208.22F1a and ACH208.13B1,
respectively). Only BC-ACH039.24E6a was passaged through
H9 cells a third time after which no further acceleration was
observed (data not shown).
Neutralization sensitivity of BC HIV-1 before and after H9 T
cell line passage
Previous studies have demonstrated that T cell line
adaptation of primary HIV-1 variants coincides with enhanced
neutralization sensitivity. Here, the sensitivity to neutralization
by sCD4 and IgG1b12 was measured for the parental viruses
and their TCLA progeny. These agents have previously beenBC-ACH208.22F1a a 32 10
b 35 24
c 42 46
d 42 39
BC-ACH208.13B1 a 57 49
b 57 39
c 70 61
d 67 24
MC-ACH320.3.1 a 24 n.d.
b 24 n.d.
c 24 n.d.
d 24 n.d.
MC-ACH320.2A 1.2 a 59 24
b 59 24
c 70 29
d 49 21
MC-pLAI/H8/E370 a 20 13
b 20 13
c 20 13
d 20 13
n.d.: Not determined.
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used here to determine the TCLA neutralization-sensitive
phenotype (Groenink et al., 1995; Moore et al., 1993). Parental
isolates BC-ACH208.22F1a and BC-ACH208.13B1 were
resistant to neutralization and required IC50 values of sCD4
and IgG1b12 that exceeded the highest concentration tested
(Table 3). TCLA progeny of BC-ACH208.22F1a showed a 13-
to 60-fold and a 4- to 8-fold increased neutralization sensitivity
for sCD4 and IgG1b12, respectively (Table 3). In contrast, 3 out
of 4 of the H9 T cell line-passaged progeny of ACH208.13B1
were still resistant to neutralization by IgG1b12 although an up
to 25-fold increased sensitivity to sCD4 neutralization, with
IC50 values ranging from 1 to 17 μg/ml, was observed. Parental
isolate BC-ACH039.24E6a was relatively sensitive to neutra-
lization by sCD4 which further increased (up to 40-fold) after
passage through H9 cells (IC50 values 17.5 and <0.4 to 15 μg/
ml, respectively). Parental and TCLA BC-ACH039.24E6a
showed identical neutralization sensitivity to IgG1b12 (IC50
of 0.4–0.9 μg/ml).
Sequence analyses of BC HIV-1 isolates before and after T cell
line adaptation
To be able to distinguish between the accumulation of novel
mutations during adaptation to growth in T cell lines and
selection of a pre-existing virus variant that was present in the
quasispecies of the parental isolate, we sequenced the V1 to V5
region of the HIV-1 envelope gene of parental and H9 passaged
viral progeny. Phylogenetic analysis of V1–V5 sequences
revealed that TCLA progeny were indeed derived from their
parental virus and that contamination could be excluded (Fig. 2).
The positions of amino acid changes after H9 passage differed
largely between the different HIV-1 isolates, although the V1/V2
and V3 region were common sites for mutations in all isolates
(Fig. 3). All four parallel H9 cell line-passaged progeny of BC-
ACH208.22F1a harbored 2 identical non-synonymous muta-
tions. For BC-ACH208.13B1, 26 (81%) of 32 mutations inTable 3
Neutralization sensitivity of the parental and H9 T cell line passaged isolates
Virus IC50
sCD4 IgG1b12
BC-ACH039.24E6a 17.5 <0.4
.a|p2 1.1 <0.4
.b|p2 15.0 0.9
.c|p2 0.7 <0.4
.d|p2 <0.4 <0.4
BC-ACH208.22F1a >25 >25
.a|p2 <0.4 4.4
.b|p2 1.2 3.6
.c|p2 1.9 6.6
.d|p2 <0.4 3.0
BC-ACH208.13B1 >25 >25
.a|p2 5.0 >25
.b|p2 1.7 6.0
.c|p2 17.2 >25
.d|p2 1.0 >25
IC50, 50% inhibitory concentration (μg/ml); |p2 refers to 2nd passage through the H9gp120 were identical between all 4 parallel H9 cell line-adapted
progeny viruses from the same split inoculum (insertions and
deletions were considered as one mutation).
If the TCLA progeny viruses would originate from a single
virus variant that was selected from the inoculum in each
parallel passage, one would expect that the genetic distance
between progeny viruses would be lower than the genetic
distance between the parental virus and its TCLA progeny.
Indeed, for both BC-ACH208.22F1a and BC-ACH208.13B1,
the genetic distance between parental isolates and TCLA
progeny was significantly larger than the genetic distance
between the four TCLA progeny viruses (Table 4). However,
the genetic distance between TCLA progeny of BC-
ACH039.24E6 was significantly larger than the genetic distance
between the parental and the TCLA viruses (Table 4).
Between parallel H9 T cell line-passaged progeny of BC-
ACH039.24E6a, only 1 out of 5 synonymous mutations and 2
out of 7 non-synonymous mutations were identical. Detailed
analysis of sequence electropherograms (data not shown) of the
parental BC-ACH039.24E6a isolate and its H9 passaged
progeny, revealed the existence of a mixed parental virus
population (Fig. 3). The genetic distance between the parental
isolate and its TCLA progeny was lower than the genetic
distance between the four TCLA progeny viruses (Table 4).
This indicates that T cell line adaptation in this case is associated
with an accumulation of novel mutations that are mostly unique
for each parallel passaged progeny.
The selection of a pre-existing T cell line-tropic variant from
the quasispecies present in the inoculum of BC-ACH208.22F1a
and BC-ACH208.13B1 but not BC-ACH039.24E6a may
depend on the heterogeneity of the isolate. We used a
heteroduplex mobility assay (HMA) to determine the hetero-
geneity of the viral quasispecies in the original inocula. HMA
revealed one band, being the homoduplex, in the inocula of BC-
ACH208.13B1 and BC-ACH039.24E6a, indicative of high
homogeneity of the inoculum (data not shown). The inoculum
of BC-ACH208.22F1a contained one additional band indicativeIC50
sCD4 IgG1b12
MC-ACH320.3*1 >25 >25
.a|p1 2.9 2.6
.b|p1 2.6 5.3
.c|p1 1.7 4.8
.d|p1 6.6 6.8
MC-pLAI/H8/E370 0.5 0.9
.a|p2 0.6 0.3
.b|p2 0.4 <0.2
.c|p2 0.4 n.d.
.d|p2 n.d. n.d.
MC-ACH320.2A 1.2 >12.5 >12.5
.a|p2 >12.5 >12.5
.b|p2 >12.5 >12.5
.c|p2 >12.5 >12.5
.d|p2 >12.5 >12.5
T cell line passages; characters before |p (a to d) are identifiers for split inocula.
Fig. 2. Phylogenetic analysis of the parental and TCLA virus variants. An initial neighbor-joining tree was reconstructed under HKY85 model using PAUP*. The NJ
tree was used as a starting tree for a heuristic search for a maximum-likelihood tree. Ams37 (Beaumont et al., 2000) is used as an out-group. Bootstrap values are
indicated, assessed with 100 rounds of replication. MC-ACH320.3.1 and MC-ACH320.2A 1.2, BC-ACH208.13B1 and BC-ACH208.22F1a cluster together in
agreement with the fact that these viruses were obtained from the same patients at two different time points.
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heterogeneity was not reflected in the very homogeneous
envelope gp120 sequences in the original inoculum of this
virus. In conclusion, we did not observe a correlation between
the heterogeneity of the inoculum and selection of a pre-
existing variant from the inoculum during T cell line
adaptation, most likely due to a very low representation of
the T cell line-tropic variants, below the limit of detection in
the HMA.T cell line adaptation of molecular cloned HIV
Our inability to correlate the selection of a pre-existing
variant to the heterogeneity of the viral quasispecies in the
inoculum prompted us to test if selection would also occur
during T cell line passage of a highly homogeneous virus
isolate. To this end we studied T cell line adaptation of four
molecular cloned (MC) HIV-1 isolates (MC-ACH320.3.1, MC-
ACH320.2A 1.2, MC-pLAI/H8/E370 and MC-pLAI/Han2).
Fig. 3. Sequence of the parental and H9 T cell line-passaged variants. The predicted amino acid sequence of the envelope glycoproteins was based on the consensus
sequence of the envelope fragment V1 to V5 that was amplified from DNA isolated from infected PBMC cultures. Sequences of passaged isolates are aligned with the
parental virus sequence. Variable and constant domains are indicated; ¶, synonymous nucleotide mutations; $, non-homogenous nucleotide sequences each consequently
leading to incorporation of a different amino acid, shown below the sequence alignment; –, insertions or deletions; dots, residues identical to parental sequence.
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Fig. 3 (continued).
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Table 4
Genetic distance between parental and TCLA isolates
Parental .2|p2 .3|p2 .4|p2 p-Value parental vs
TCLA progeny
BC-ACH208.13B1 a 0
.b|p2 0.0252 0
.c|p2 0.0240 0.0033 0
.d|p2 0.0234 0.0068 0.0057 0 <0.001
Parental .1|p2 .2|p2 .3|p2 .4|p2
BC-ACH208.22F1a 0
.a|p2 0.0020 0
.b|p2 0.0020 0 0
.c|p2 0.0020 0 0 0
.d|p2 0.0020 0 0 0 0 <0.001
Parental .1|p2 .2|p2 .3|p2 .4|p2
BC-ACH039.24E6a 0
.a|p2 0.0029 0
.b|p2 0.0049 0.0078 0
.c|p2 0.0039 0.0068 0.0068 0
.d|p2 0.0020 0.0049 0.0049 0.0039 0 0.0302
a BC-ACH208.13B1.a|p2 was not included in the calculation of the genetic distance as its sequence was too short (C2-V4 only).
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shown and Groenink et al., 1991; Sauermann et al., 1990). As
for the BC-HIV-1 isolates, separate PBMC cultures produc-
tively infected with one of the MC viruses were split in four
equal aliquots (a–d) that were co-cultured with H9 cells (p1;
Fig. 1). At day 21, p24 levels in all cultures had become
undetectable, indicating that the remaining PBMC in the co-
culture no longer produced viral progeny above the limit of
detection of our in-house ELISA. Parallel H9 co-cultures with
split inocula of MC-pLAI/H8/E370 infected PBMC (p1)
showed first evidence of p24 gag antigen production on day
20 while co-cultures with MC-ACH320.2A 1.2 infected PBMC
(p1) required 49–70 days (Table 2). The second parallel H9
passages (p2) of MC-pLAI/H8/E370 and MC-ACH320.2A 1.2
showed evidence of virus production on day 13 and between
days 21 and 29. Again, culture times did not further decrease
after a third serial passage on H9 cells (data not shown). These
data indicate that also MC HIV-1 variants can adapt to growth
in T cell lines during multiple passages. Parallel H9 cell co-
cultures with MC-ACH320.3.1 infected PBMC were first
positive for p24 production on day 24. No subsequent passages
were performed with this virus. H9 cells inoculated with MC-
pLAI/Han2 did not show evidence of virus production for
more than 80 days after initiation of the co-culture (data not
shown).
Neutralization sensitivity of MC HIV-1 before and after H9 T
cell line passage
Next we measured the neutralization sensitivity of parental
MC HIV-1 variants and their TCLA progeny. Parental isolates
MC-ACH320.3.1 and MC-ACH320.2A 1.2 required IC50
values for sCD4 and IgG1b12 that exceeded the highest
concentration tested. TCLA progeny of MC-ACH320.3.1showed a 4- to 15-fold increased neutralization sensitivity for
sCD4 and IgG1b12 (Table 3). In contrast, the H9 passaged
progeny from MC-ACH320.2A 1.2 was still resistant to sCD4
and IgG1b12 with IC50 values exceeding the highest concen-
tration tested (12.5 μg/ml). MC-pLAI/Han2 was also resistant to
neutralization by sCD4 and IgG1b12 (data not shown). MC-
pLAI/H8/E370 was relatively sensitive to neutralization by
sCD4 and IgG1b12, which did not increase upon H9 T cell line
passage. IC50 values of parental and progeny clones varied from
0.2 to 0.9 μg/ml for both sCD4 and IgG1b12 (Table 3).
Sequence analyses of MC HIV-1 isolates before and after T cell
line adaptation
To reveal molecular changes in gp120 potentially associated
with adaptation to the H9 T cell line we sequenced proviral
DNA from parental and TCLA progeny. Parental and TCLA
progeny of MC-ACH320.3.1 and the TCLA progeny of MC-
ACH320.2A 1.2 and MC-pLAI/H8/E370 revealed evidence for
the presence of mixed virus populations (double peaks in the
electropherogram; data not shown and Fig. 3). For MC-
ACH320.3.1, none of the five amino acid changes in the 4
parallel obtained TCLA progeny from the same split inoculum
were identical and no synonymous mutations were observed
(Fig. 3).
Despite the equal neutralization sensitivity of the parental
MC-ACH320.2A 1.2 and its TCLA progeny there were 7
mutations (1 synonymous and 6 non-synonymous mutations) of
which 2 were identical in all 4 progeny viruses obtained after
parallel H9 cell line passage of aliquots from the same split
inoculum.
Genetic distances within TCLA progenies and between
TCLA progeny and the parental isolate were not different (data
not shown) suggesting that here TCLA progeny did not
Fig. 4. Heteroduplexes mobility analysis of short-term (wk1) and long-term
(wk32) of BC-ACH208.22F1b (lanes 2–4) and inoculum, short-term and
long-term PBMC cultured BC-ACH039.24E6b (lanes 6–11). The V1 to V5
region of gp120 was PCR amplified. Heteroduplexes were formed by melt-
ing DNA at 95 °C and reannealing by rapid cooling on wet ice. Hetero-
duplexes were analyzed by electrophoresis on a 5% non-denaturing poly-
acrylamide gel.
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in the inoculum.
HIV neutralization sensitivity after prolonged culture in PBMC
The selection of a pre-existing variant during T cell line
passage of 2 of 3 BC HIV-1 isolates but not during T cell line
adaptation of early passages of 4 MC HIV-1 variants urged us to
establish whether the emergence of more T cell line-tropic
neutralization-sensitive variants during prolonged in vitro
culture on primary PBMC is a more general phenomenon
than previously assumed (Beaumont et al., 2004; Pugach et al.,
2004). To this end, BC-ACH208.22F1b and BC-
ACH039.24E6b were cultured for 32 weeks on primary
PBMC. Fresh PHA-stimulated PBMC were added every
week. After 32 weeks, culture supernatants were harvested
and tested for infectious virus titer and subsequently for
neutralization sensitivity for sCD4 and IgG1b12. Long-term
passaged BC-ACH208.22F1b and BC-ACH039.24E6b showed
a 31- and 47-fold increased neutralization sensitivity for sCD4,
respectively (Table 5). The IgG1b12 IC50 value for long-term
passaged BC-ACH208.22F1b was almost 60-fold decreased,
but only slightly decreased for long-term passaged BC-
ACH039.24E6b, which may be due to the already relatively
high neutralization sensitivity of the parental virus.
HIV-1 quasispecies diversity after prolonged culture on PBMC
To determine changes in viral quasispecies diversity during
prolonged culture in PBMC, we performed a heteroduplex
mobility assay on BC-ACH208.22F1b and BC-ACH039.24E6b
after short-term and long-term PBMC culture (Fig. 4). HMA
of the short-term cultured BC-ACH208.22F1b (lane 2, Fig. 4)
showed only the homoduplex, indicative of a very homo-
genous virus population. HMA of long-term cultured BC-
ACH208.22F1b revealed two additional slower migrating
heteroduplex bands. This indeed suggested an ongoing
evolution and increasing heterogeneity of the viral quasis-
pecies during prolonged PBMC culture in vitro.
HMA of the parental BC-ACH039.24E6b virus revealed a
homoduplex and two heteroduplex bands (Fig. 4, lane 6).
Heterogeneity did not change during the first 7 days of culture
and HMA of mixed PCR product of the HIV-1 envelopes
present in the inoculum and after 7 days of culture showed
exactly the same bands as the separate samples indicating thatTable 5
Neutralization sensitivity of parental HIV-1 and its long-term PBMC passaged
progeny
Virus IC50
sCD4 IgG1b12
BC-ACH039.24E6b >12.5 2.5
Week 32 0.4 <0.2
BC-ACH208.22F1b 9.5 >12.5
Week 32 0.2 <0.2
IC50, 50% inhibitory concentration (μg/ml).diversity had not increased during short-term PBMC culture.
Long-term culture of BC-ACH039.24E6b did result in an
increased number of slower migrating heteroduplexes. The
larger number of heteroduplexes revealed in a HMA of mixed
PCR products of the viral envelopes in the wk1 and wk32
quasispecies than in the wk32 quasispecies alone confirms the
ongoing evolution and an increasing diversity of the viral
quasispecies of HIV-1 during replication in PBMC in vitro.
Competition for replication in PBMC between a parental
HIV-1 isolate and its TCLA progeny
MConsidering the apparent coexistence of neutralization-
resistant parental virus and its neutralization-sensitive pro-
geny, we next tested their relative fitness in a direct
competition experiment. PBMC were infected with a total
of 100 TCID50. Each inoculum harbored a different ratio of
the parental isolate BC-ACH208.13B1 and its progeny
ACH208.13B1.b|p2 (0:100, 25:75, 50:50, 75:25 and 100:0
of ACH208.13B1: ACH208.13B1.b|p2). A PCR with primers
spanning a region in the V4 domain which contains an insert
in progeny virus ACH208.13B1.b|p2 but not in the parental
virus BC-ACH208.13B1 was used to distinguish between the
two virus variants (Fig. 5). Irrespective of the ratio of the twoFig. 5. Analysis of in vitro replication fitness/competition between BC-
ACH208.13B1 parental and progeny virus. PHA-stimulated PBMC were
inoculated with mixtures of different ratios of parental BC-ACH208.13B1 virus
and one of its TCLA progeny. Viruses were distinguished by a PCRwith primers
spanning an insert of six amino acids that is present in the V4 loop of the
ACH208.13B1.b|p2 H9 passaged isolate (200 bp) but absent in the parental BC-
ACH208.13B1 isolate (182 bp; see Materials and methods for detailed
description and Fig. 3 for sequences).
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evidence of virus production on day 5 after inoculation. PCR
analysis on proviral DNA in the PBMC obtained at day 12
after inoculation revealed the presence of both variants. These
experiments show that neutralization-resistant and sensitive
HIV-1 variants can coexist, at least in short term PBMC
cultures, indicating limited fitness difference between the
clones.
Discussion
Adaptation of primary HIV-1 to growth in permanent T cell
lines coincides with an increase in sensitivity to neutralization
by antibodies and sCD4 (Kozak et al., 1997; Moore et al.,
1993; Moore et al., 1995; Moore and Ho, 1995; Sawyer et al.,
1994; Zhang et al., 1997). Whether this phenotypic change
was due to an accumulation of de novo mutations or selection
of a pre-existing, neutralization-sensitive T cell line-tropic
variant has not been resolved. Our group and others have
previously shown that neutralization-sensitive HIV-1 variants
can emerge during culture in PBMC (Beaumont et al., 2004;
Pugach et al., 2004). We here show that T cell line adaptation
of frequently passaged but originally clonal HIV-1 variants
may indeed select for pre-existing, presumably more T cell
line-tropic virus variants that have emerged in the quasispecies
in the inoculum. Indeed, the genetic distance between 4
progeny viruses of parallel T cell line passages from the same
inoculum was smaller than the genetic distance between the
parental virus and its TCLA progeny for 2 of 3 BC HIV-1
variants studied here.
We assumed that viral inocula from which a pre-existing T
cell line-tropic variant could be selected would have a higher
diversity than inocula from which selection did not occur. How-
ever, HMA analysis of the inoculum of BC-ACH208.13B1,
from which most likely a pre-existing variant was selected
during T cell line passage, did not reveal a heterogeneous viral
quasispecies. This may be due to the threshold of the HMA
assay to pick up minor variants (limit of detection is minor
variants that represent 2–5% of the viral population; Delwart
et al., 1994).
The degree of mismatches between the parental and TCLA
progeny of BC-ACH208.22F1a was below 2% and hetero-
duplexes that would correspond with this low level variation
were not observed. This is in agreement with a detection limit of
10% sequence variation in the HMA (Upchurch et al., 2000).
However, HMA analysis of BC-ACH208.22F1a did reveal a
very slow migrating heteroduplex band, indicating the presence
of 2 highly divergent virus variants in the inoculum that were
not detected in the sequence analysis. Apparently, minor
variants that have a prevalence below the detection limit of
sequence analysis may be detected depending on the variation
of the sequences.
During prolonged culture of primary HIV-1 variants in
PBMC an increase in heterogeneity was observed which also
coincided with an increased neutralization sensitivity. T cell line
adaptation of highly homogeneous MC HIV-1 variants was
much more difficult and did not involve selection of a pre-existing variant but required an accumulation of de novo
mutations.
Although it has been demonstrated that prolonged culture
of an R5 HIV-1 also resulted in a virus variant with increased
neutralization sensitivity (Pugach et al., 2004), we restricted
our present study to X4 variants only, due to the fact that the
available U87-CCR5 expressing cell line in our hands did not
select for neutralization-sensitive R5 virus variants (data not
shown). Passage through the highly HIV-1 susceptible MT2
cell line did also not select for a single variant from the
quasispecies and progeny virus did not have an increased
neutralization sensitivity (data not shown). The H9 T cell line
was the only CXCR4 expressing cell line that could select for
pre-existing neutralization-sensitive HIV-1 variants, which is
most likely due to unique expression levels of CD4 and
CXCR4. These low expression levels of CD4 and CXCR4
might indeed select for virus variants which more efficiently
use CD4 and/or CXCR4. As parental viruses and TCLA
progeny had equal sensitivities to CXCR4 antagonist
AMD3100 (data not shown) it is unlikely that the efficiency
by which coreceptor CXCR4 is used is the underlying
mechanism by which TCLA viruses are selected. Selection of
virus variants with increased efficiency of CD4 usage thus
seems the most likely mechanism.
We realize that conclusive evidence for selection of a pre-
existing variant would come from showing the actual
presence of this variant in the inoculum. We designed a
nested PCR (limit of detection 10 copies HIV DNA/5×104
cells) with primers flanking the insertion in the V4 domain of
the BC-ACH208.13B1 variant obtained after T cell line
adaptation. However, despite more than hundred PCR
reactions of cloned envelope fragments from the original
inoculum, we were unable to demonstrate the presence of the
variant that was selected on the H9 T cell line (data not
shown). This may suggest that the neutralization-sensitive T
cell line-tropic virus variant represents only a very minor
virus population in the quasispecies of the PBMC culture.
The low abundance of these T cell line-tropic viruses could
point to an initial low fitness of these variants. Although we
did not observe a difference in fitness between a neutraliza-
tion-sensitive and resistant variant during short-term PBMC
culture, it seems likely that neutralization resistance comes at
a fitness cost. The increased neutralization sensitivity of HIV-
1 early in infection before neutralizing antibodies have
emerged (Derdeyn et al., 2004; Frost et al., 2005; Wei et
al., 2003) indeed suggests that gain of fitness associated with
this phenotype may select for viruses with a neutralization-
sensitive phenotype. This may also explain why in vitro, in
the absence of neutralizing antibodies, neutralization-sensitive
HIV-1 variants can emerge although we had anticipated that
these variants would have dominated the viral quasispecies
much more rapidly than observed here. Alternatively or in
addition, PBMC may harbor cells that phenotypically
resemble permanent T cell lines that allow or select for
HIV variants with a potentially more open neutralization-
sensitive envelope configuration. In stimulated PBMC
cultures, the expression of HIV receptors and coreceptors
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finding a target cell and/or specific cellular niches (Kozak et
al., 1997; Lapham et al., 1999; McKnight et al., 1995; van Rij
et al., 2000). It is tempting to speculate that this mechanism
would also support the emergence of neutralization-sensitive
virus variants in vivo. Although type-specific neutralizing
antibodies seem to be directed against the viruses that have
escaped the preceding type-specific neutralizing antibodies, it
is an unresolved paradigm how HIV-1 elicits broadly
neutralizing antibodies if it at the same time resists their
neutralizing effect by hiding its vulnerable epitopes. In
contrast to neutralization-resistant HIV-1 variants with
occluded epitopes, the neutralization-sensitive virus variants
may be able to present the relevant epitopes, triggering
production of broadly reactive HIV-1-specific neutralizing
antibodies by which they obviously are subsequently
neutralized.
The underlying mechanism for the selection of neutraliza-
tion-sensitive virus variants on T cell lines is unknown. It has
been hypothesized that an envelope configuration that is
optimally adapted to replicate in permanent T cell lines is
also more accessible to neutralizing antibodies (Moore and
Ho, 1995). Consequently, HIV-1 variants with relatively high
neutralization sensitivity may adapt more easily to growth in
permanent T cell lines. Indeed, we here observed that
parental HIV-1 variants with a relatively high sCD4 and
IgG1b12 neutralization sensitivity, were readily able to
replicate in the H9 T cell line. In contrast, viruses that
were neutralization-resistant required more than 8 weeks or
completely failed to establish infection in the H9 T cell line.
The difficulty for several HIV-1 variants to persistently infect
the H9 T cell line suggests that multiple mutations may be
required to achieve T cell line tropism. This is also in line
with the observation that the period before first day of
detection of viral replication in the H9 T cell line co-culture
decreased with subsequent passages.
Our data confirm that, probably depending on the genetic
background of the virus, different mutations can lead to a
neutralization-sensitive phenotype. Moreover, in none of the
viruses, mutations involved amino acid positions that are
considered to be in direct contact with CD4, as determined by
Kwong et al. (1998), and that could directly explain changes in
neutralization sensitivity for sCD4 and IgG1b12. Although we
restricted our sequence analysis to gp120, which was sufficient
for our phylogenetic analysis, needless to say that a role for
gp41 in the neutralization sensitivity of HIV-1 is definitely not
excluded.
In summary, we here show that T cell line adaptation of HIV-
1 may select for a pre-existing virus variant with increased
neutralization sensitivity that may have emerged during in vitro
culture on primary cells, and is most competent to replicate in T
cell lines. Whether these neutralization-sensitive HIV-1 variants
can also temporarily evolve in vivo in HIV-1-infected
individuals, thereby exposing relevant epitopes for eliciting
neutralizing antibodies, remains to be established and would
have implications for our current ideas of HIV-specific humoral
immunity and vaccine design.Materials and methods
Cells
Experiments were performed on a pool of phytohemagglu-
tinin (PHA) stimulated peripheral blood mononuclear cells
(PBMC) of five healthy blood donors with a CCR5 wild type
genotype (CCR5+/+). PBMC were isolated from buffy coats by
Ficoll density centrifugation. For stimulation, 5×106 cells/ml
were cultured for 2–3 days in Iscove's modified Dulbecco's
medium (IMDM) supplemented with 10% fetal bovine serum
(FBS, Perbio, Logan, Utah, USA), penicillin (100 U/ml, Gibco,
Paisly, Scotland, UK), streptomycin (100 μg/ml, Gibco),
ciproxin (5 μg/ml, Bayer, Mijdrecht, The Netherlands) and
PHA (5 μg/ml, Remel Europe, Dartford, England, UK).
Subsequently, PHA-stimulated cells (106/ml) were grown in
the absence of PHA, in medium supplemented with 10 U/ml
recombinant interleukin 2 (Chiron Benelux BV, Amsterdam,
The Netherlands). The H9 T cell line was cultured in IMDM
supplemented with 10% FBS, penicillin (100 U/ml) and
streptomycin (100 μg/ml).
Viruses
For virus stock preparation, virus titration and subsequent
neutralization experiments, the same pool of PHA-stimulated
PBMC were used. Viruses were obtained by multiple limiting
dilution co-cultures, as described previously (Van 't Wout et al.,
1998). From two participants of the Amsterdam Cohort Studies
on HIV infection and AIDS (ACS), biologically cloned (BC)
isolates 24E6a from patient ACH039, and 13B1 and 22F1a
from ACH208 were used (Table 1).
ACH320.3.1 and ACH320.2A 1.2 are two full-length
molecular clones isolated from the same patient of which high
molecular weight DNA of the first one was previously obtained
after short-term passage through H9 cells, and for the second
one from infected PBMC (Groenink et al., 1991). pLAI-H8/
E370 is a full-length molecular clone that was previously
generated (Beaumont et al., 2004). pLAI-Han2 is a full-length
molecular clone in which the SalI-BamHI envelop gene
fragment of the Han2 virus (Sauermann et al., 1990) is cloned
in the background of pLAI. The entire envelope of the Han2
virus strain was amplified by PCR using the Expand High
Fidelity kit (Roche) with primer combinations AD1 (5′-
TTTCAGAATTGGGTGTCGACATAGC-3′, positions 5771–
5795 relative to HxB2) and AD2 (5′-GATAAGTGCCAAG-
GATCCGT-3′, positions 8472–8491) and conditions as
described previously (Beaumont et al., 2001; Van 't Wout et
al., 1998). PCR products were purified with the GFX
Purification Kit (Amersham Pharmacia, Buckinghamshire,
England, UK) and inserted into the pGEM-T easy vector
(Promega, Madison, WI, USA). To ensure proper ligation of the
inserts, the resulting plasmids were sequenced using BigDye
Terminator v1.1 Cycle Sequencing kit (ABI Prism, Applied
Biosystems, Warrington, UK), according to the manufacturer's
protocol. The full-length molecular clone and virus stocks were
obtained as described previously (Beaumont et al., 2004).
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HIV-1 isolates ACH208.22F1b and ACH039.24E6b that
were obtained via biological cloning, were used for short-
term and long-term cultures on primary PHA-stimulated
PBMC. BC-ACH039.24E6a and BC-ACH039.24E6b are
different stock preparations of the same biological clone.
This is also the difference between BC-ACH208.22F1a and
BC-ACH208.22F1b.
During prolonged PBMC culture, fresh PHA-stimulated
PBMC were added weekly and cultures were regularly tested
for virus production in the supernatant using an in house p24
antigen capture ELISA (Tersmette et al., 1989). Every week,
PBMC DNA and culture supernatant containing virus were
stored at −80 °C and every 4 weeks viable HIV-1-infected cells
were cryopreserved.
H9 cell line passage
Four equal amounts of HIV-1-infected PBMC (2.5×106)
were co-cultivated in parallel with a mixture of 2.5×106
freshly PHA-stimulated PBMC and 5×106 H9 cells (Fig. 1) in
culture medium lacking IL-2 and PHA. Cultures were
microscopically examined twice a week and were refreshed
depending on cell growth. With regular intervals, H9 cell
cultures that remained negative for p24 production were
cultured in medium supplemented with IL2 to increase cell
activation and virus transcription. Cultures were maintained for
at least 2 months. Supernatant of H9 cell cultures was harvested
when p24 antigen could be detected by ELISA. Given that the
H9-PBMC co-cultures had been negative for p24 production
before this harvest, we excluded that the virus detected in the
supernatant at this time was unlikely to have been produced by
the PBMC that were used for the initial co-cultivation. For the
second and third sequential passages, a fixed volume of cell-
free supernatant of the first (1.5 ml) and second passage (1 ml),
respectively, was used (Fig. 1). Stocks from H9 cell line-
passaged progeny virus were prepared on PBMC and used for
testing neutralization sensitivity.
In four parallel passages of the molecularly cloned (MC)
ACH320.3.1 on the H9 cell line, p24 production in the culture
supernatant remained below the limit of detection of our in-
house p24 ELISA (10 ng/ml). However, virus production could
be demonstrated in all cultures when tested in a commercially
available p24 ELISA with a detection limit of 50–1000 pg/ml
p24 (HIVAG-1 Monoclonal, Abbott) (data not shown). As
viruses that were subsequently rescued by co-cultivation of H9
cells with PHA-stimulated PBMC showed characteristics of
TCLA HIV-1 (see below), we assume that this low level p24
antigen is a reflection of low level replication rather than
preserved replication-competent virus from the inoculum.
Sensitivity to neutralization by CD4 binding site (CD4-bs)
directed agents
Viruses were tested for their relative neutralization sensitiv-
ity against increasing concentrations of sCD4 (Progenics,Tarrytown, NY, USA and NIH AIDS reagent program) and the
MAb IgG1b12 (Burton et al., 1994). From each virus isolate,
an inoculum of 400 TCID50/ml in a 100 μl final volume was
incubated for 1 h at 37 °C with increasing concentrations of the
neutralizing agents. Subsequently, 105 3-day PHA-stimulated
human PBMC were added to the mixtures of virus with sCD4
or IgG1b12 in 96-well microtiter plates. On days 7 and 14 virus
production in supernatants was analyzed by p24 production
using an in-house p24 ELISA. Percent neutralization was
calculated as the mean reduction in p24 production of triplicate
cultures in the presence of the neutralizing agent compared to
cultures with virus only. Fifty percent inhibitory concentrations
(IC50) were determined by linear regression when possible.
Characterization of virus replication
Differences in replication rate between the parental BC
isolate ACH208.13B1 and the H9 passaged progeny
ACH208.13B1.b|p2 were studied in a competition assay
performed on PHA-stimulated PBMC. Prior to inoculation,
virus stocks were treated with DNase (200 ng/ml; RQ1;
Promega Corp., Madison, WI) for 30 min at 37 °C in a final
concentration of 12 mM MgCl2. PHA-stimulated PBMC (5 ×
106) were incubated for 2 h at 37 °C with a total of 100 TCID50
in a final volume of 1 ml. The different ratios of ACH208.13B1
and ACH208.13B1.b|p2 that were used for inoculation were
100:0, 75:25, 50:50, 25:75 and 0:100. Cells were washed and
incubated at a final concentration of 106 cells/ml. At days 3, 5,
7, 10, 12 and 14, 50 μl of supernatant and 5×105 cells were
harvested for analysis of virus production and DNA isolation,
respectively. At day 7, 3 × 106 freshly stimulated PBMC were
added. The level of co-infection by the two isolates could be
distinguished by a non-quantitative PCR reaction spanning an
insertion of six amino acids in the V4 region of the
ACH208.13B1.b|p2 isolate (Fig. 3). First, high molecular
weight DNA (5 μl) was subjected to 30 cycles of PCR, using
a set of primers spanning the complete gp120 region (Beaumont
et al., 2001). In a nested PCR reaction primer EnvH (pos. 7361,
relative to HXB2) and reverse primer Seq6 (pos. 7556) (5′-
GGGGAATTTTTCTACTGTAATTCAACACAACTGTT-3′
and 5′-ATCTAATTTGTCCACTGATGGGAGG-3′, respec-
tively) were used to amplify the fragment that did
(ACH208.13B1.b|p2) or did not (ACH208.13B1) contain the
insert.
Heteroduplex mobility assay
The extent of quasispecies diversity in short- and long-term
PBMC cultures was determined using a heteroduplex mobility
assay. To this end, DNAwas obtained from infected PBMC by
L6 DNA isolation (Boom et al., 1991). First, complete gp120
was PCR amplified, followed by a nested PCR of the V1 to V5
region of gp120 using the Expand High Fidelity kit (Roche)
with seq1 and seq2 primers (5′-TAATGTTTGGGCCACA-
CATGCC-3′ and 5′-TCCCTCATATCTCCTCCTCCAAGTC-
3′). Heteroduplexes were formed by melting combined or single
DNAs at 95 °C and reannealing them by rapid cooling on ice.
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denaturing polyacrylamide gel as described previously (Delwart
et al., 1993) and visualized by staining with ethidium bromide.
Sequence analysis
Total DNA was isolated from HIV-infected PBMC and the
complete HIV-1 envelope gene was PCR amplified using the
Expand High Fidelity PCR system (Roche Diagnostics,
Mannheim, Germany). Primer combinations and PCR condi-
tions were described previously (Beaumont et al., 2001). PCR
products were purified using GFX Purification Kit (Amersham
Pharmacia). Sequencing was performed using BigDye Termi-
nator v1.1 Cycle Sequencing kit (ABI Prism, Applied
Biosystems), according to the manufacturer's protocol on an
ABI 377 automated sequencer (Applied Biosystems).
Nucleotide sequences of all parental and progeny variants
were aligned using DAMBE (Xia and Xie, 2001) and edited
manually. An initial neighbor-joining tree was reconstructed
under Hasegawa–Kishino–Yano model (HKY85) of evolution
(Hasegawa et al., 1985) using PAUP* (Swofford, 2002). The NJ
tree was used as a starting tree for a heuristic search for a
maximum-likelihood tree. Bootstrap analysis was assessed with
100 rounds of replication.
Genetic distances were calculated on aligned nucleotide
sequences using the Kimura-2 parameter model in PAUP*.
Statistical analysis
Statistical analysis was performed using the two-sample t-
test assuming equal variances. A result was considered
significant if the P value was<0.05. Two-tailed P values are
indicated.
Nucleotide sequence accession numbers
Sequences obtained in this study are submitted to Genbank.
Accession numbers are EF-028243 to EF028272.Acknowledgments
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